Key Clinical Summary: 

• Design/Population: In this single-arm, phase 2 trial, 125 previously treated patients with platinum-sensitive ovarian cancer expressing FRα received mirvetuximab soravtansine plus carboplatin followed by mirvetuximab maintenance. 
• Key Outcomes: The combination achieved an ORR exceeding 60%, with additional responses during maintenance therapy. Median progression-free survival was approximately 11 months, with activity observed across subgroups, including those with prior PARP inhibitor exposure.
• Clinical Relevance: FRα-targeted therapy combined with chemotherapy may offer a treatment option in platinum-sensitive ovarian cancer. These findings support further evaluation of mirvetuximab-based strategies in this setting.

Results from the phase 2 IMGN853-0420 study demonstrate that mirvetuximab soravtansine plus carboplatin shows encouraging clinical activity with manageable safety among patients with platinum-sensitive ovarian cancer expressing folate receptor alpha (FRα).

These findings were presented by Gottfried Konecny, MD, University of California, Los Angeles, California, at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting in San Juan, Puerto Rico.

In this single-arm study, 125 patients with measurable, recurrent FRα-expressing platinum-sensitive ovarian cancer who had received 1 prior line of platinum-based chemotherapy received 6 mg/kg of mirvetuximab soravtansine (adjusted by ideal body weight) plus carboplatin (AUC 5) every 3 weeks for 6 to 8 cycles, followed by mirvetuximab soravtansine monotherapy. The primary end point was objective response rate (ORR) in both the overall population and the FRα ≥ 50% population (n = 102). Key secondary end points included duration of response, progression-free survival (PFS), overall survival (OS), and safety. 

At analysis, the confirmed ORR was 62.7% in the FRα ≥ 50% population, with 9 complete responses and 55 partial responses. The confirmed ORR was 62.4% in the overall population. Following maintenance therapy, additional responses increased ORR to 68%. Median duration of response was 11.2 months, and median PFS was 11 months. OS data were immature. Activity was observed across subgroups, including patients previously treated with PARP inhibitors (n = 61). 

The most frequently reported treatment-related adverse events included grade 1/2 blurred vision (81%) and corneal events (74%), which improved to grade ≤ 1 in 90% of patients. Grade ≥3 adverse events occurred in 65% of patients and were driven by hematologic adverse events in 26% of patients. Grade ≥3 adverse events occurred during study treatment in 81% of patients. Mirvetuximab soravtansine and/or carboplatin dose reductions (54%) and treatment discontinuations (20%) were mainly due to hematologic (7%), respiratory (7%), and ocular (2%) adverse events. The rate of adjudicated pneumonitis was 15%, of which 4% were grade ≥ 3, and led to 2 deaths in patients with preexisting cardiopulmonary disorders. 

Results show “comparable efficacy to pre-PARP [inhibitor] era benchmarks and established for the first time the safety and efficacy of continuing [mirvetuximab soravtansine] after carboplatin,” concluded Dr Konecny. “These findings support further evaluation of [mirvetuximab soravtansine] plus carboplatin as a meaningful treatment option in recurrent [platinum-sensitive ovarian cancer].” 

Source: 

Konecny G, Lim P, Santin A, et al. Mirvetuximab soravtansine plus carboplatin in folate receptor alpha-expressing recurrent platinum-sensitive ovarian cancer. Presented at SGO Annual Meeting on Women’s Cancer. April 10 - 13, 2026; San Juan, Puerto Rico. LBA5.